| Full Name | Michael Hope |
|---|---|
| Gender | Male |
| Speciality | Licensed Practical Nurse |
| Location | 7 Lyons St, Rochester, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316510654 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 016219-22 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Hope, 7 Lyons St, Rochester, NH 03867-1858 Ph: (603) 973-3974 | Michael Hope, 7 Lyons St, Rochester, NH 03867-1858 Ph: (603) 973-3974 |
News Archive
An analysis of nationally-representative data indicates that between 1988 and 2010 there has been a trend of declining average levels of total cholesterol, non-high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol for U.S. adults overall, according to a study in the October 17 issue of JAMA.
Several presentations by deCODE genetics scientists and independent researchers at the American Heart Association Scientific Sessions 2008 being held at the New Orleans Convention Center from November 8 to12 are expected to expand upon the clinical utility of evaluating individual risk of heart attack, or atrial fibrillation and stroke, respectively, by measuring the genetic markers that are the basis of the deCODE MI and deCODE AF tests.
Male hormonal contraceptives applied daily to the skin reduce sperm production, finds a new study to be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
The COVID-19 pandemic has magnified the social, educational and health care disparities already plaguing the nearly 40 million Americans the U.S. Census Bureau estimates are living in poverty.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.
› Verified 2 days ago
Deborah Curley, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 25 Old Dover Rd, Rochester, NH 03867 Phone: 603-516-9300 |